Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ID93 + GLA-SE (Quratis)
- Development stage
- Unknown
- Lead developer
- Quratis
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ID93 + GLA-SE (also known as QTP101) is a subunit tuberculosis vaccine candidate being developed by Quratis Inc. in collaboration with the Access to Advanced Health Institute (AAHI). The vaccine is composed of two primary components: ID93, a recombinant fusion protein comprising four Mycobacterium tuberculosis antigens (Rv3619, Rv1813, Rv3620, and Rv2608), and GLA-SE, an adjuvant containing a synthetic Toll-like receptor 4 (TLR4) agonist (glucopyranosyl lipid adjuvant) formulated in a stable oil-in-water emulsion. Designed as a booster for individuals previously vaccinated with the Bacillus Calmette-Guérin (BCG) vaccine, ID93 + GLA-SE aims to prevent TB infection and disease by eliciting potent Th1-cell-mediated immune responses and humoral immunity. Clinical development has progressed through Phase 2a trials in healthy healthcare workers and Phase 1 trials in adolescents, with Phase 2b/3 trials planned to further evaluate efficacy and safety.
- Other names
- ID93/GLA-SE
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on ID93 + GLA-SE (Quratis).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ID93 + GLA-SE (Quratis).